ADVFN Logo ADVFN
Donnée du Marché
Actualité
Outils
Donnée du Marché
Discover

Hot Features

Follow Feed

Rester connecter avec les traders et investisseurs dans notre communauté Follow Feed.

Flux des Options

Explorez des données complètes sur les options et utilisez les filtres avancés avec Options Flow.

Moniteur

Organisez et surveillez vos d'actions et actifs avec le Moniteur.
Se connecter Premium IconPremium Help Menu
CAC 40
7 503,27
-2,66%
Dow Jones
38 589,16
-0,15%
DAX
18 002,02
-1,43%
Brent Oil
82,275
0,00%
Bitcoin
66 140,10
0,20%
Registration Strip Icon for charts Inscrivez-vous pour des graphiques en temps réel, des outils d'analyse et des prix.
S'inscrire
  1. Accueil
  2. Investir
  3. Actions
  4. Etats-Unis
  5. NASDAQ
  6. Acasti Pharma Inc (ACST)

  7. Acasti Pharma Inc (ACST) Actualités

ACST

Acasti Pharma (ACST)

Acasti Pharma Inc
De:
Trier par:
 Showing the most relevant articles for your search:NASDAQ:ACST
DateHeureSourceTitreSymboleSociété
10/05/202422h11Edgar (US Regulatory)Form 4/A - Statement of changes in beneficial ownership of securities: [Amend]NASDAQ:ACSTAcasti Pharma Inc
09/05/202401h19Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:ACSTAcasti Pharma Inc
12/02/202414h00Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:ACSTAcasti Pharma Inc
12/02/202413h30Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:ACSTAcasti Pharma Inc
08/01/202414h00Edgar (US Regulatory)Form 3 - Initial statement of beneficial ownership of securitiesNASDAQ:ACSTAcasti Pharma Inc
17/10/202306h15Edgar (US Regulatory)Form EFFECT - Notice of EffectivenessNASDAQ:ACSTAcasti Pharma Inc
16/10/202322h31Edgar (US Regulatory)Form 424B3 - Prospectus [Rule 424(b)(3)]NASDAQ:ACSTAcasti Pharma Inc
10/10/202313h40Edgar (US Regulatory)Form D - Notice of Exempt Offering of SecuritiesNASDAQ:ACSTAcasti Pharma Inc
06/10/202322h30Edgar (US Regulatory)Form S-3 - Registration statement under Securities Act of 1933NASDAQ:ACSTAcasti Pharma Inc
25/08/202323h01Edgar (US Regulatory)Form S-8 - Securities to be offered to employees in employee benefit plansNASDAQ:ACSTAcasti Pharma Inc
25/08/202322h21Edgar (US Regulatory)Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) materialNASDAQ:ACSTAcasti Pharma Inc
25/08/202322h15Edgar (US Regulatory)Form DEF 14A - Other definitive proxy statementsNASDAQ:ACSTAcasti Pharma Inc
10/07/202315h00PR Newswire (US)Acasti Announces WuXi Clinical as CRO to Conduct STRIVE-ON Pivotal Phase 3 Safety Trial for GTX-104 in aSAH PatientsNASDAQ:ACSTAcasti Pharma Inc
07/07/202314h00PR Newswire (US)Acasti Pharma Announces 1-for-6 Reverse Stock SplitNASDAQ:ACSTAcasti Pharma Inc
05/07/202315h00PR Newswire (US)Acasti Announces Alignment with FDA on GTX-104 Pivotal Phase 3 Safety Trial Protocol and Confirms Planned Initiation of STRIVE-ON in aSAH Patients in Calendar Q4 2023NASDAQ:ACSTAcasti Pharma Inc
23/06/202313h02Edgar (US Regulatory)Annual Report (10-k)NASDAQ:ACSTAcasti Pharma Inc
23/06/202313h00PR Newswire (US)Acasti Pharma Reports Fiscal Year 2023 Operational ResultsNASDAQ:ACSTAcasti Pharma Inc
22/06/202315h00PR Newswire (US)Acasti Announces Appointment of New Scientific Advisory Board MembersNASDAQ:ACSTAcasti Pharma Inc
26/05/202321h07Edgar (US Regulatory)Initial Statement of Beneficial Ownership (3)NASDAQ:ACSTAcasti Pharma Inc
17/05/202315h00PR Newswire (US)Acasti to Participate in the Lytham Partners Spring 2023 Investor ConferenceNASDAQ:ACSTAcasti Pharma Inc
08/05/202313h00PR Newswire (US)Acasti Successfully Submits Pivotal GTX-104 Phase 3 Safety Study Protocol with FDA and Implements Strategic Realignment Plan That Extends Projected Cash Runway Through Calendar Q2 2025NASDAQ:ACSTAcasti Pharma Inc
05/04/202323h01Edgar (US Regulatory)Current Report Filing (8-k)NASDAQ:ACSTAcasti Pharma Inc
04/04/202314h01PR Newswire (US)Acasti to Proceed with Phase 3 Clinical Safety Study for GTX-104 Following FDA Feedback, and Upon Approval of the Full Study Protocol to be Submitted to the INDNASDAQ:ACSTAcasti Pharma Inc
04/04/202314h00PR Newswire (US)Acasti Announces Appointment of Prashant Kohli as CEONASDAQ:ACSTAcasti Pharma Inc
30/03/202314h30PR Newswire (US)Acasti Pharma Inc. Announces the Resignation of a DirectorNASDAQ:ACSTAcasti Pharma Inc
13/03/202313h00PR Newswire (US)Acasti Pharma Inc. Centralizes Marketplace for Shares on the Nasdaq with Voluntary Delisting from TSX Venture ExchangeNASDAQ:ACSTAcasti Pharma Inc
08/03/202315h00PR Newswire (US)Acasti Pharma to Participate in Oppenheimer 33rd Annual Healthcare ConferenceNASDAQ:ACSTAcasti Pharma Inc
28/02/202319h00PR Newswire (US)Acasti Pharma Recognizes Rare Disease DayNASDAQ:ACSTAcasti Pharma Inc
14/02/202313h02Edgar (US Regulatory)Quarterly Report (10-q)NASDAQ:ACSTAcasti Pharma Inc
14/02/202313h00GlobeNewswire Inc.Acasti Pharma Reports Third Quarter 2023 Operational ResultsNASDAQ:ACSTAcasti Pharma Inc
 Showing the most relevant articles for your search:NASDAQ:ACST

Dernières Valeurs Consultées

TSXV
TVT.P
GATE
LITHUSDT
Lithium
NASDAQ
AAYJJXX
Hsbc Usa Inc Point to Po...
TSXV
AFA
GATE
BEPROUSDT
BetProtocolToken
COIN
HPBEUR
High-Performance Blockchain
LATK
FANUSDT
Fanfare Global Token
LSE
BUR4
Burf Cap.f25
ASX
EGA
Egan Street Resources
LSE
72FJ
Hsbc Bk. 23
ASX
PTR
Petratherm
BIT
UR9E0B
UniCredit Bank
HITB
EVXETH
Everex
BIT
UR9QAR
UniCredit Bank
BIT
P10U81
Bnp Paribas Issuance
LSE
QL38
Morg.st.b.v 25
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

France
Société
Entreprise
Popular
Obtenir l'application
App Store
Google Play

Assistance: support@advfn.fr

En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales

© 2024 ADVFN PLC - Tous droits réservés